102 Cardiology Conferences: "Hydralazine and Isosorbide Dinitrate” & "New and Emerging Therapies for Lipid Lowering" (091422)
Dallas, TX US
September 14, 2022
To provide scholarly presentations in cardiology or disciplines related to cardiovascular disease.
Target Audience
UT Southwestern faculty, fellows, students and staff
Learning Objectives
At the conclusion of this activity, participants should be able to (1) Review 2 clinical topics in cardiology (30 minutes each) with specific attention to analyzing recent literature regarding advances in diagnosis and treatment of cardiovascular disease; (2) Discuss clinical topics in areas outside of cardiology that impact our patient population.
UT Southwestern Medical Center
5323 Harry Hines Blvd
William P. Clements Jr. University Hospital – Lecture Hall
Dallas, TX
75235
United States
Course Director(s)
Parag Joshi, MD, MHS
has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Grant Or Contract) with Novo Nordisk;.
has a financial relationship (Grant Or Contract) with NASA;.
has a financial relationship (Stock Options) with Global Genomics Group;.
has a financial relationship (Grant Or Contract) with Amgen;.
has a financial relationship (Grant Or Contract) with AstraZeneca;.
Peer reviewer(s)
Anish Bhatt, MD
has no relevant financial relationships to disclose at this time.
Speaker(s)
Spencer Carter, MD
has no relevant financial relationships to disclose at this time.
Ann Navar, MD, PhD, FAHA, FACC, FASPC
has a financial relationship (Independent contractor) with Amarin, Amgen, Astra Zeneca, BI, Bayer, BMS, CSL, Esperion, Janssen, Lilly, Sanofi, NovoNordisk, Novartis, New Amsterdam, Cerner, and Pfizer;.
has a financial relationship (Grant Or Contract) with BMS, Esperion, Amgen, and Janssen;.
has a financial relationship (Independent contractor) with Cerner Corporation;.
Available Credit
- 1.00 AMA
- 1.00 Attendance
Price
Cost:
$0.00
Please login or create an account to take this course.